<DOC>
	<DOCNO>NCT01937390</DOCNO>
	<brief_summary>The objective study observe effect adherence once-daily administer long-acting bronchodilator ( long-acting ß2-agonists [ LABAs ] / long-acting muscarinic antagonist [ LAMAs ] ) patient health relate quality life ( HR-QoL ) ass relation symptom improvement adherence Chronic Obstructive Pulmonary Disease ( COPD ) maintenance therapy</brief_summary>
	<brief_title>Observational Study Adherence LABA / LAMA Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female , 40 year age 2 . Patients clinically diagnose COPD history suggestive asthma : 1. score &gt; =5 COPD Population Screener , 2. clinical diagnosis COPD make pulmonologists internist , 3. Forced Expiratory Volume ( FEV1 ) / Forced Vital Capacity ( FVC6 ) ratio &lt; =0.70 FEV1 &lt; =80 % predict value assess copd6 ( Vitalograph , UK ) ; 3 . Maintenance treatmentnaïve COPD patient prescribe daily longacting bronchodilator ( LABAs / LAMAs ) first time enrolment study 4 . Patients able provide sign informed consent 5 . Patients agree contact telephone/ SMS reminder via call center Exclusion criterion : 1 . Patients contraindication prescribed medication 2 . Patients disorder would prevent patient able complete questionnaire either verbally selfcompletion 3 . Pregnant lactate woman woman childbearing potential use acceptable method contraception</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>